The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Celsion (CLSN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of CLSN and the rest of the Medical group's stocks.
Celsion is a member of the Medical sector. This group includes 844 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CLSN is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for CLSN's full-year earnings has moved 17.02% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CLSN has returned 53.19% so far this year. Meanwhile, the Medical sector has returned an average of 3.81% on a year-to-date basis. This shows that Celsion is outperforming its peers so far this year.
Breaking things down more, CLSN is a member of the Medical - Biomedical and Genetics industry, which includes 352 individual companies and currently sits at #78 in the Zacks Industry Rank. On average, stocks in this group have gained 3.54% this year, meaning that CLSN is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CLSN as it looks to continue its solid performance.